EP1229913A1 - 1-benzazepines substituees et leurs derives - Google Patents

1-benzazepines substituees et leurs derives

Info

Publication number
EP1229913A1
EP1229913A1 EP00977008A EP00977008A EP1229913A1 EP 1229913 A1 EP1229913 A1 EP 1229913A1 EP 00977008 A EP00977008 A EP 00977008A EP 00977008 A EP00977008 A EP 00977008A EP 1229913 A1 EP1229913 A1 EP 1229913A1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
compound
benzazepine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00977008A
Other languages
German (de)
English (en)
Other versions
EP1229913A4 (fr
Inventor
Alenka Tomazic
Liren Huang
Kenneth D. Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Antex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Pharma Inc filed Critical Antex Pharma Inc
Publication of EP1229913A1 publication Critical patent/EP1229913A1/fr
Publication of EP1229913A4 publication Critical patent/EP1229913A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to novel substituted 1- benzazapines and derivatives thereof useful as antibacterials, to pharmaceutical compositions comprising such compounds, to processes for making these compounds and to methods of using these compounds for treating bacterial infections.
  • Benzazepine compounds are useful in a number of pharmaceutical applications.
  • U.S. Patent No. 5,786,353 discloses that tricyclic benzazepine is useful as a vasopressin antagonist.
  • U.S. Patent No. 5,247,080 discloses that substituted benzazepines are useful as intermediates for producing pharmaceutically active compounds, such as intermediates for compounds that have valuable properties in treating psychosis, depression, pain and hypertension.
  • WO 97/24336 discloses a process for the aminocarbonylation of benzazepines and benzodiazepines . These compounds are used as intermediates for preparing pharmaceutically active compounds.
  • Tetrahydro-1-benzazepines and tetrahydro- 1, 4 -benzodiazepines form the core structure of a variety of pharmaceutically useful compounds.
  • WO 93/00095 PCT/US92/05463
  • WO 94/14776 PCT/US93/12436
  • 4- PCT/US92/05463
  • WO 94/14776 PCT/US93/12436 disclose 7- aminocarbonyl tetrahydro-1-benzazepines and tetrahydro-1
  • 4- benzodiazepines which are reported to be inhibitors of the fibrinogen and vitronectin receptors and useful as inhibitors of platelet aggregation, osteoporosis, angiogenesis and cancer metastasis .
  • Methods to prepare such compounds typically employ a trisubstituted phenyl derivative as a starting material.
  • the trisubstituted phenyl derivative incorporates two substituents to form the azepine and/or diazepine ring, and a third substituent to introduce the 7-carbonyl substituent.
  • Such starting materials may be difficult and costly to obtain, and may limit the chemistry which may be employed to form the azepine ring.
  • Prior processes generally introduce the aminocarbonyl group into the molecule via a 7-carboxyl group which is coupled to an amino group by conventional methods for forming amide bonds. Methods disclosed in WO 93/00095 and WO 94/14776 are exemplary.
  • Bacterial infections are a significant and growing medical problem. They occur when the body's immune system cannot prevent the invasion and colonization of the body by disease-causing bacteria. These infections may either be confined to a single organ or tissue, or disseminated throughout the body, and can cause many serious diseases, including pneumonias, endocarditis, osteomyelitis, meningitis, deep-seated soft tissue infections, bacteremia and complicated urinary tract infections. According to estimates from the United States Centers for Disease Control and Prevention (the "CDC") in 1995, approximately 1.9 million hospital-acquired infections occurred in the United States, accounting for more than $4.5 billion in additional health care costs each year and contributing to more than 88,000 deaths. While overall per capita mortality rates declined in the United States from 1980 to 1992, the per capita mortality rate due to infectious diseases increased 58% over this period, making infectious diseases the third leading cause of death in the United States.
  • CDC Centers for Disease Control and Prevention
  • Antibiotics are administered both to prevent bacterial infections and to treat established bacterial diseases.
  • antibiotics When administered to prevent an infection, antibiotics are given prophylactically, before definitive clinical signs or symptoms of an infection are present.
  • antibiotics When administered to treat an established infection, antibiotics are often chosen empirically, before diagnostic testing has established the causative bacterium and its susceptibility to specific antibiotics.
  • Antibiotics work by interfering with a vital bacterial cell function at a specific cellular target, either killing the bacteria or arresting their multiplication, thereby allowing the patient ' s immune system to clear the bacteria from the body.
  • Currently available antibiotics work on relatively few targets, through mechanisms such as inhibiting protein or cell wall synthesis. These targets tend to be present in all bacteria and are highly similar in structure and function, such that certain antibiotics kill or inhibit growth of a broad range of bacterial species (i.e., broad-spectrum antibiotics) .
  • antibiotics include beta-lactams, quinolones, macrolides, tetracyclines, aminoglycosides, glycopeptides and trimethoprim combinations.
  • Penicillin a member of the beta-lactam class (which also includes extended-spectrum penicillins, cephalosporins and carbapenems)
  • Nalidixic acid the earliest member of the quinolone class, was discovered in the 1960s.
  • the creation of broad-spectrum antibiotics began in the 1970s and 1980s, with major advances seen in the 1970s with the development of newer beta-lactams, and in the 1980s with the development of fluoro uinolones . These antibiotics are still being used extensively. No major new class of antibiotics has been discovered and commercialized in the last 20 years. There remains a need to identify new classes of antibiotics to fight bacterial infections and to overcome the increasing resistance by bacteria to currently marketed antibiotics.
  • the instant invention is directed to novel substituted 1-benzazepine compounds of the Formula (I) :
  • Ar is aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl;
  • Aa is -CX (NH 2 ) C0 2 H, wherein X signifies a group that completes a natural or synthetic amino acid;
  • R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
  • Q is 0 or S
  • Z is 0 or S; a and b are each a single or double bond, and when a is a double bond, only R 2 or R 3 is present; m is 0, 1 or 2 ; n is 1, 2 or 3 ; and pharmaceutically acceptable salts or prodrug forms thereof .
  • R 1 is H
  • R 4 and R 5 are independently H, halogen, -N0 2 , -CN, substituted or unsubstituted, straight chain, branched or cyclic, alkyl, alkenyl, or alkynyl, substituted or unsubstituted -Ar or
  • R 1 is alkyl, alkylfluorophenyl, alkyl nitrile
  • R 4 and R 5 are independently H, halogen, alkoxy, -OR, substituted or unsubstituted piperazinyl with the proviso that R 4 and R 5 cannot both be H
  • a and b are single bonds.
  • Specifically preferred compounds of the present invention include:
  • the present invention also provides methods for the treatment of bacterial, viral or fungal infection by administering to a host infected with bacteria, virus or fungus a pharmaceutically effective amount of a compound of formula (I)
  • R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted, straight chain, branched or cyclic, alkyl, alkenyl, or alkynyl, substituted or unsubstituted -Ar or -(CH 2 ) n Ar, - (CH 2 ) m N (R) 2 , - (CH 2 ) m NH (Aa) ,
  • R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
  • Q is 0 or S
  • Z is 0 or S; a and b are each a single or double bond, and when a is a double bond, only R 2 or R 3 is present; m is 0, 1 or 2; n is 1, 2 or 3 ; and pharmaceutically acceptable salts or prodrug forms thereof .
  • the present invention provides compounds and methods for the treatment of central nervous system (CNS) disorders, inflammatory diseases, cardiovascular diseases, cancers including angiogenesis, pain, allergic disorders, autoimmune disorders and immunoregulation.
  • CNS central nervous system
  • Another aspect of the invention is directed to processes for making the compounds of the present invention, including the steps of introduction of a carboxyl group into the 1-benzazepine skeleton.
  • any variable for example, R 1 through R 5 , R, Ar, Aa, Q, Z, m, n, etc.
  • its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • alkyl means a branched or unbranched saturated aliphatic hydrocarbon radical, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms .
  • alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec- butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2- dimethylpropyl , n-hexyl, 2-methylpentyl, 2 , 2-dimethylbutyl, n- heptyl, 2-methylhexyl, and the like.
  • the terms “lower alkyl” and “C ⁇ -C 6 alkyl” are synonymous and used interchangeably.
  • a preferred "C ⁇ -C ⁇ alkyl” group is methyl or ethyl.
  • alkenyl means a branched or unbranched hydrocarbon radical having the number of carbon atoms designated containing one or more carbon-carbon double bonds, each double bond being independently cis, trans, or a nongeometric isomer.
  • alkynyl means a branched or unbranched hydrocarbon radical having the number of carbon atoms designated containing one or more carbon-carbon triple bonds.
  • substituted alkyl, alkenyl, alkynyl denotes the above alkyl, alkenyl or alkynyl groups that are substituted by one, two or three; halogen (F, Cl, Br, I) , nitro, cyano, hydroxy, alkoxy, haloalkoxy, cyclic, branched or unbranched lower alkyl, cyclic, branched or unbranched lower alkenyl, cyclic, branched or unbranched lower alkynyl, protected hydroxy, amino, protected amino, C; L -C 6 acyloxy, carboxy, protected carboxy, carbamoyl, carbamoyloxy, and methylsulfonylamino.
  • the substituted alkyl, alkenyl, and alkynyl groups may be substituted once, twice or three times with the same or with different substituents.
  • Examples of the above substituted alkyl groups include but are not limited to: cyanomethyl, nitromethyl, hydroxymethyl , trityloxymethyl, propionyloxymethyl, aminomethyl , carboxymethyl , alkyloxycarbonylmethyl , allyloxycarbonylaminomethy1 , carbamoyloxymethyl , methoxymet yl , ethoxymethyl , t-butoxymethyl, acetoxymethyl , chloromethyl , bromomethyl, iodomethyl, trifluoromethyl, 6- hydroxyhexyl , 2 ,4-dichloro (n-butyl) , 2-amino (isopropyl) , 2- carbamoyloxyethyl and the like.
  • a preferred group of examples within the above "substituted alkyl” group includes the substituted methyl group and substituted ethyl group.
  • Examples of the substituted methyl group include groups such as hydroxymethyl, protected hydroxymethyl (e.g., tetrahydro- pyranyloxymethyl) , acetoxymethyl, carbamoyloxymethyl , trifluoromethyl, chloromethyl, bromomethyl and iodomethyl.
  • alkyloxy or “alkoxy” are used interchangeably herein and denote groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups .
  • acyloxy or alkanoyloxy
  • alkanoyloxy are used interchangeably and denote herein groups such as formyloxy, 16 acetoxy, propionyloxy, butyryloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy and the like.
  • alkylcarbonyl , “alkanoyl” and “acyl” are used interchangeably herein encompass groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like.
  • cycloalkyl refers to a mono-, bi- or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms .
  • alkylthio and substituted alkylthio denote alkyl and substituted alkyl groups, respectively, attached to a sulfur which is in turn the point of attachment of the alkythio or substituted alkylthio group to the group or substituent designated.
  • Ar as used herein and in the claims denotes any partially saturated aromatic, or aromatic, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, and heteroaryl generally known to those skilled in organic chemistry and as further described herein below.
  • Substituted Ar denotes any substituted, partially saturated aromatic, or aromatic, aryl, substituted arylalkyl, and substituted heteroaryl which are generally known to those skilled in organic chemistry and as further described herein below, that include but are not limited to those groups wherein one or more hydrogens are substituted by one, two or three: halogen (F, Cl, Br, I), nitro, cyano, hydroxy, protected hydroxy, alkoxy, haloalkoxy, cyclic, branched or unbranched lower alkyl, cyclic, branched or unbranched lower alkenyl, cyclic, branched or unbranched lower alkynyl, substituted with amino, protected amino, cyano, nitro, aminomethyl, C ⁇ -C 6 acyloxy, carboxy, protected carboxy, carboxymethyl, hydroxymethyl, carbamoyl, carbamoyloxy, trifluoromethyl, N- (methylsulfonylamino) , methyl
  • aryl denotes any mono-, bi- or tricyclic partially saturated aromatic ring or aromatic ring having 5-21 carbon atoms, where at least one ring is a 5-, 6- or 7- membered hydrocarbon ring, and containing from zero to four heteroatoms selected from nitrogen, oxygen and sulfur.
  • Preferred hydrocarbon aryl groups include phenyl, napthyl, biphenyl, phenanthrenyl, naphthacenyl and the like (see Lang' s Handbook of Chemistry (Dean, J.A. , ed) 14 th Ed., [1992]).
  • substituted phenyl include but are not limited to a mono- or di (halo) phenyl group such as 4-chlorophenyl, 2 , 6-dichlorophenyl, 2 , 5-dichlorophenyl, 3,4- dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3 , 4-dibromophenyl, 3-chloro-4-fluorphenyl, 2 -fluorophenyl and the like; a group such as 4-hydroxyphenyl, 3-hydroxyphenyl , 2 , 4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 3- or 4-nitrophenyl ; a cyanophenyl group, for example, 4-cyanophenyl; a mono or di (lower alkyl) phenyl group such as 4-methylphenyl, 2,4- dimethylphenyl
  • substituted phenyl represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro- 4- hydroxyphenyl , 2-methoxy-4-bromophenyl, 4 -ethyl-2- hydroxyphenyl , 3-hydroxy-4-nitrophenyl, 2-hydroxy-4- chlorophenyl and the like.
  • Preferred substituted phenyl groups include the 2- and 3 -trifluoromethylphenyl, the 4- hydroxyphenyl , the 2-aminomethylphenyl and the 3-(N- (methylsulfonylamino) ) phenyl groups.
  • arylalkyl means one, two or three aryl groups having 3 to 14 carbon atoms, appended to an alkyl radical having 1 to 12 carbon atoms including but not limited to: benzyl, napthylmethyl , phenethyl, benzyhydryl (diphenylmethyl) , trityl piperazinylmethyl, pyrimidinylethyl, pyridazinylpropyl, indolylbutyl, purinylmethyl and the like.
  • substituted arylalkyl denotes an alkyl group substituted at any carbon with a C 6 -C ⁇ 2 aryl group bonded to the alkyl group through any aryl ring position and substituted on the C ⁇ -C 6 alkyl portion with one, two or three groups chosen from halogen (F, Cl, Br, I) , straight chain, branched or cyclic C ⁇ -C 6 alkyl, straight chain, branched or cyclic C ⁇ -C 6 alkenyl, straight chain, branched or cyclic C ⁇ -C 6 alkynyl, hydroxy, protected hydroxy, amino, protected amino,
  • halogen F, Cl, Br, I
  • the aryl group may be substituted with one, two or three groups chosen from halogen, straight chain, branched or cyclic C ⁇ -C 6 alkyl, straight chain, branched or cyclic Ci-C ⁇ alkenyl, straight chain, branched or cyclic Ci-
  • substituted arylalkyl examples include groups such as 2 -phenyl-1-chloroethyl, 2- (4- methoxyphenyl) ethyl, 2 , 6-dihydroxy-4 -phenyl (n-hexyl) , 5-cyano-
  • heterocycle Unless otherwise specified, the terms “heterocycle” , “heterocyclic group”, “heterocyclic” or “heterocyclyl” are used interchangeably herein and includes any mono-, bi- or tricyclic saturated, unsaturated or aromatic ring where at least one ring is a 5-, 6- or 7-membered hydrocarbon ring containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, preferably at least one heteroatom is nitrogen ⁇ Lang' s Handbook of Chemistry, vide supra) .
  • the heterocycle is a 5- or 6 -member saturated, unsaturated or aromatic hydrocarbon ring containing 1, 2, or 3 heteroatoms selected from O, N and S.
  • the 5-membered ring has 0 to 2 double bonds and the 6- or 7- membered ring has 0 to 3 double bonds and the nitrogen or sulfur heteroatoms may optionally be oxidized, and any nitrogen heteroatom may optionally be quarternized.
  • Included in the definition are any bicyclic groups where any of the above heterocyclic rings are fused to a benzene ring. Heterocyclics in which nitrogen is the heteroatom are preferred.
  • heterocyclic whether substituted or unsubstituted radicals denoted by the term "heterocyclic”: thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazinyl, oxazinyl, triazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl, oxathiazinyl, tetrazinyl, thiatriazinyl, oxatriaziny
  • Heterocyclic 5-membered ring systems containing a sulfur or oxygen atom and one to three nitrogen atoms are also suitable for use in the instant invention.
  • Examples of such preferred groups included thiazolyl in particular thiazol-2-yl and thiazol-2-yl N-oxide, thiadiazolyl, in particular 1,3,4- thiadiazol-5-yl and 1, 2 , 4-thiadiazol-5-yl, oxazolyl, preferably oxazol-2-yl, and oxadiazolyl, such as 1,3,4- oxadiazol-5-yl, and 1, 2, 4-oxadiazol-5-yl .
  • a group of further preferred examples of 5-membered ring systems with 2 to 4 nitrogen atoms include imidazolyl, preferably imidazol-2-yl; triazolyl, preferably 1, 3 , 4-triazol-5-yl; 1, 2 , 3-triazol-5-yl, 1, 2,4-triazol-5-yl and tetrazolyl, preferably lH-tetrazol-5- yl .
  • a preferred group of examples of benzo-fused derivatives are benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl .
  • heterocylic ring systems are 6-membered ring systems containing one to three nitrogen atoms .
  • Such examples include pyridyl, such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, preferably pyrimid-2-yl and pyrimid-4-yl; triazinyl, preferably 1, 3 , 4-triazin-2-yl and 1, 3 , 5-triazin-4- yl; pyridazinyl, in particular pyridazin-3-yl and pyrazinyl.
  • pyridine N-oxides and pyridazine N-oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the 1, 3 , 4-triazin- 2-yl radicals are a preferred group.
  • preferred 6- membered ring heterocycles are: piperazinyl, piperazin-2-yl, piperidyl, piperid-2-yl, piperid-3-yl, piperid-4-yl, morpholino, morpholin-2-yl and morpholin-3-yl .
  • heterocyclics include: 1, 3-thiazol-2-yl, 4- (carboxymethyl) -5-methyl-1 , 3- thiazol-2-yl, 4- (carboxymethyl) -5-methyl- 1, 3-thiazol-2-yl sodium salt, 1, 2 , 4-thiadiazol-5-yl, 3-methyl-l, 2 , 4-thiadiazol- 5-yl, 1, 3,4-triazol-5-yl, 2-methyl-l, 3 , 4-triazol-5-yl, 2- hydroxy-1, 3 , 4-triazol-5-yl, 2 -carboxy-4 -methyl-1, 3 , 4-triazol- 5-yl sodium salt, 2-carboxy-4-methyl-l, 3 , 4-triazol-5-yl, 1,3- oxazol-2-yl, 1, 3 , 4-oxadiazol-5-yl, 2-methyl-l, 3 , 4-oxadiazol-5- yl, 2- (hydroxymethyl) -1, 3 ,
  • An alternative group of "heterocyclics” includes: 4- (carboxymethyl) -5-methyl-1,3-thiazol-2 -yl , 4- (carboxymethyl) - 5-methyl-l, 3-thiazol-2-yl sodium salt, 1, 3 , 4-triazol-5-yl, 2- methyl-1, 3 , 4-triazol-5-yl, lH-tetrazol-5-yl, 1-methyl-lH- tetrazol-5-yl, 1- (1- (dimethylamino) eth-2-yl) -lH-tetrazol-5-yl, 1- (carboxymethyl) -lH-tetrazol-5-yl, 1- (carboxymethyl) -1-H- tetrazol-5-yl sodium salt, 1- (methylsulfonic acid) -1H- tetrazol-5-yl, 1- (methylsulfonic acid) -lH-tetrazol-5-yl sodium salt, 1, 2, 3-tria
  • heteroaryl group or “heteroaryl” are used interchangeably herein and includes any mono-, bi- or tricyclic aromatic rings having the number of ring atoms designated where at least one ring is a 5-, 6- or 7-membered hydrocarbon ring containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, preferably at least one heteroatom is nitrogen.
  • the aryl portion of the term “heteroaryl” refers to aromaticity, a term known to those skilled in the art and defined in greater detail in "Advanced Organic Chemistry” , J . March, 4 th Ed., John Wiley & Sons, New York, N.Y. (1992) .
  • Aa refers to "amino carboxylic acid” as that term is generally understood by those skilled in the art and denotes any group having -CX(NH 2 C0 2 H) , wherein X signifies a group that completes a natural or synthetic amino acid.
  • Typical natural aminoacids include but are not limited to alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. Any other amino acid, natural or synthetic, are contemplated within the scope of this invention.
  • primary amine as used herein and in the claims is generally understood by those skilled in the art and denotes any group which is attached to an amine (-NH 2 ) moiety, and includes but is not limited to alkyl-amines, alkenyl- amines, alkynyl-amines, aryl-amines and herteroaryl-amines, as such terms are described herein above.
  • primary amines include, but are not limited to any of those listed above, as well as for example, guanidine, methylguanidine , 1, 10-diaminodecane, 1,4- diaminobutane , 5-amino-indazole, 7-amino-4- (trifluoromethyl) - coumarin, 4 -bromo-3- (trifluoromethyl) aniline, 3-chloro-4- fluoroaniline, 2-chloro-5- (trifluoromethyl) aniline, 3,5- difluorobenzylamine, 2- (difluoromethoxy) aniline, 3-fluoro-p- anisidine, 2-fluoroethylamine, 3-fluoro-4-methylaniline, 4- fluorophenylethylamine, 3-fluoro-d-phenylalanine, 3-fluoro-l- phenylalanine, d, 1, -3-fluorophenylalanine, 4-fluoro-3- (trifluor
  • second amine as used herein and in the claims is generally understood by those skilled in the art and denotes any two groups which are attached symmetrically or unsymmetrically to an amino (-NH-) moiety.
  • secondary amines include, but are not limited to any of those listed above, as well as for example, piperazine, pyrrolidine, 3- ( ert-butoxycarbonylamino) - pyrrolidine, 1-benzylpiperazine, benzyl-1-piperazine carboxylate, 4-benzylpiperidine, 1- (2-chlorophenyl) piperazine, 2,6 dimethylmorpholine, ethyl isonipecotate, ethyl-1- piperazinecarboxylate, 1- (4-fluorophenyl) piperazine, heptamethyleneimine, 1- (2-methoxyphenyl) piperazine, 1- methylhomopiperazine, 1-methylpiperazine, morpholine, 1- (4- nitrophenyl) piperazine, 1-phenylpiperazine, 1- phenylpiperazine, 4 ' -piperazinoacetophenone, piperidine, 4- piperidinopiperadine, 1- (2 -pyridyl,
  • pharmaceutically acceptable salts and prodrugs refer to derivatives of the disclosed compounds that are modified by making acid or base salts, or by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
  • compositions of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 19th ed. , Mack Publishing Company, Easton, PA, 1995, p. 1418, the disclosure of which is hereby incorporated by reference.
  • Pharmaceutically acceptable acid addition salts are those salts which retain the biological effectiveness and properties of the free bases and which are not biologcially or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.
  • inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid,
  • Pharmaceutically acceptable base addition salts are those derived from inorganic bases such as sodium, potasium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
  • Prodrugs are considered to be any covalently bonded carriers which release the active parent drug in vivo when such prodrug is administered to a subject.
  • Prodrugs of the compounds of the parent compound are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
  • Prodrugs include, but are not limited to, compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and acetyl and benzoyl derivatives of amine functional groups in the compounds of the invention and the like.
  • stable compound or “stable structure” is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
  • carboxy-protecting group refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups of the compound.
  • carboxylic acid protecting groups include 4-nitrobenzyl, 4-methoxybenzyl, 3,4- dimethoxybenzyl , 2, 4-dimethoxybenzyl, 2 , 4 , 6-trimethoxybenzyl, pentamethylbenzyl, 3 , 4-methylenedioxybenzyl, benzhydryl, 4,4'- dimethoxybenzhydryl , 2 , 2' , 4 , 4 ' -tetramethoxybenzhydryl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'- di ethoxytrityl, 4 , 4' , 4" trimethoxytrityl, 2-phenylprop-2-
  • carboxy-protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the condition of subsequent reaction (s) on other positions of the 1-benzazepine molecule and can be removed at the appropriate point without disrupting the remainder of the molecule.
  • it is important not to subject the carboxy-protected 1-benzazepine molecule to strong nucleophilic bases or reductive conditions employing highly activated metal catalysts such as Raney nickel. (Such harsh removal conditions are also to be avoided when removing amino- protecting groups and hydroxy-protecting groups, discussed below.)
  • Preferred carboxylic acid protecting groups are the allyl, tert-butyl and p-nitrobenzyl groups. Similar carboxy- protecting groups used in the cephalosporin, penicillin and peptide arts can also be used to protect a carboxy group substituents of the 1-benzazepine .
  • amino-protecting group refers to any group typically used in the peptide art for protecting the peptide nitrogens from undesirable side reactions.
  • groups include 3 , 4-dimethoxybenzyl, benzyl, p-nitrobenzyl, di- (p-methoxyphenyl) methyl, triphenymethyl, (p-methoxyphenyl) diphenylmethyl , N-5 -dibenzosuberyl , trimethylsilyl, t-butyl dimethylsilyl and the like. Further descriptions of these protecting groups can be found in
  • substituted ⁇ - tetralones are well known in the art of organic synthesis and numerous methods for their preparation are published. Conversion of substituted ⁇ - tetralones 1 to benzo-fused lactams 3 can be achieved by a number of methods proceeding via the intermediate, corresponding oxime 2, that may be isolated or used as is. Suitable methods for transformation 1 to 3 involve the use of the Beckmann Rearrangement or Schmidt reaction. The key intermediate 3 is then deprotonated with an inert base such as LDA or Li-hexamethyl disilazide and the like.
  • an inert base such as LDA or Li-hexamethyl disilazide and the like.
  • reaction typically such reactions are carried out in, for instance, but not limited to THF, dioxane, ether at temperatures -78°C to 25°C.
  • Numerous electrophilic reagents can capture an anion, formed on ⁇ - position relative to amide functionality.
  • the intermediate 4 may be again reacted with an inert base in an inert solvent, followed by an attack of an electrophile to give disubstituted products on 3- position of the 1- benzazepine-2-one ring. Subsequently, an alkyl group may be introduced on the hetero-atom as shown in General Scheme A.
  • bases may include, but are not limited to Cs 2 C0 3 , K 2 C0 3 , NaH, KH while alkylating reagents would include, but are not limited to ethyl bromide, ethyl iodide, diethyl sulfate, 2-bromoethanol and the like. Solvents would include, but are not limited to acetonitrile, acetone, DMA, DMF and the like. Alkylations of this kind are usually run at 25°C to 100°C. Thus obtained intermediate 5 may represent a final NCE or may be further elaborated.
  • the 7- bromo of the intermediate 6 is displaced preferentially using a nucleophilic amine such as piperazine, methyl piperazine, tert-butyl 1- piperazinecarboxylate and benzyl 1- piperazinecarboxylate.
  • a nucleophilic amine such as piperazine, methyl piperazine, tert-butyl 1- piperazinecarboxylate and benzyl 1- piperazinecarboxylate.
  • Co-bases such as K 2 C0 3 , Cs 2 C0 3 , NaOBu c , KOBu*, K3PO4 and the like are usually used to capture hydrogen halides that are generated in the relevant reactions.
  • R 4 Y represents a compound wherein R 4 is defined according to the invention and Y is a leaving group that allows R 4 to be inserted into the ring.
  • Y includes but is not limited to -SnBu 3 (tributyl tin), Sn(CH 3 ) 3 and -B(OH) 2 .
  • aryls and heteroaryls may also be introduced at X on the benzo-fused lactams ring when X is Br, I, Cl or triflate using palladium or cupric catalyzed couplings of tin or boronate carbocycles, aryls and heteroaryls.
  • the relevant methodologies are well known in the art and are described by literature methods such as those published by Chan D.M.T., et al (vide infra); Kamikawa K. , et al J. Org. Chem. 1998, 63, 8407-8410 and Stille, et al . , Angew. Chem.
  • Solvents such as DCM, chloroform, toluene are generally employed in the latter deprotection reactions which are run at ambient temperature to 70°C and require 2 hours to 48 hours. The resulting hydroxyl group should be protected again in order to further embellish the intermediate
  • the dimethyl tert-butyl silyl protecting group of the intermediate 12 may be removed by tetrabutylammonium fluoride or acid treatment.
  • SCHEME C 14 An alkylation of 13 can be carried out with inert bases such as K 2 C0 3 , Cs 2 C0 3 , NaHC0 3 and the like.
  • Solvents are typically, but are not limited to dioxane, DMF, DMA, and DMSO, acetone, acetonitrile and the like. Temperatures are 25°C to 125°C. Alkylating reagents in the latter cases are limited to alkyl and substituted benzyl iodides and bromides.
  • the reaction can be performed under very mild reaction conditions, i. e. room temperature and with an amine base. It should be noted that the yield of the reaction can be quite dependent on the nature of the substrate and the substitution on the boronic acid.
  • the choice of the tertiary amine base, i.e., triethylamine versus pyridine also plays a critical role in determining the yield of the reaction.
  • Arylboronic acids in place of triarylbismuth represent an attractive alterantive in O-arylations since a large number of organo boronic acids are either commercially available or their syntheses are well described in the literature.
  • Some arylboronic acids can be obtained from Aldrich Chem Corp. or
  • the phenol type derivative 13 of substituted 1- benzazepine-2-one can be transformed into the corresponding triflate intermediate by any method known in the protecting art. Subsequently, the intermediate 15 can be subjected to a coupling reaction with a variety of the amines using Pd(0) catalyst mediated reactions.
  • the leaving group is a triflate
  • organotin reagents and organoboronates may be used with palladium catalysts to render a carbon nucleophile. In this way all sorts of alkyl, aryl and heteroaryl groups may be introduced in the l-benzazepine-2-one ring as it was discussed before and indicated in the General Scheme B.
  • Substituted anilines, exemplified by 17, serve as a starting material, which can be alkylated by using reductive condensation with a variety of aldehydes (alkyl, aryl and heteroaryl) .
  • the substituents R 3 , R 4 , R 5 of the starting aniline 17 can be chosen from an array of groups that are indicated on the aromatic ring in the Structural Formula I .
  • Reductive aminations are well known in the art and are typically performed in alcohols, water/alcohol mixtures or in water/DMF mixtures at temperatures 25°C to 80°C.
  • N-alkylated anilines can be further acylated using any 3 -chloro 3-oxopropionate (alkyl/benzyl malonyl chloride) as a reagent of choice to synthesize the intermediate 19 as shown in General Scheme D .
  • the ester group of the intermediate 19 can be later in the synthesis transformed into carboxyl, amino carbonyl or hydroxymethyl group.
  • the 19-type intermediates are very well known in the chemistry of quinolones. Elongation of a carbon chain on the hetero-atom with tert-butylbromoacetate, for instance, provides an appropriate substrate for a subsequent Friedel Crafts reaction.
  • a cyclization of 20 can be achieved by a number of methods well known in the literature as Friedel-Crafts reaction.
  • a cyclization of 20 to 21 can be effected, for instance, in one pot reaction via the mixed anhydride formed with triflie acid.
  • Introduction of a double bond is examplified but not limited to a conversion of 21 to 22.
  • Dehydrogenation of the intermediate 21 can be carried out using diphenyl diselenide+ LDA, phenylselenyl chloride, DDQ, benzeneselenic anhydride, formed in situ, selenium dioxide in water or any appropriate reagent known in the dehydrogenation art.
  • solvents would include dioxane, THF, benzene, chlorobenzene, acetic acid, ethanol at temperatures 25°C to 120 °C. These latter reactions usually require 2 hrs to 48 hours.
  • a prolongation of the chain on the hetero-atom of the intermediate 19 is effected by using bromoacetaldehyde ethylene acetal, for instance, in the presence of inert bases such as LDA or Cs 2 C0 3 the intermediate 23 is obtained.
  • inert bases such as LDA or Cs 2 C0 3
  • strong acidic reaction conditions affords the desired compound 24.
  • strong acids would include p-toluene sulfonic acid or PPA at elevated temperatures. 24 can be considered a NCE or an intermediate that can be further embellished.
  • 8-methoxy-2 ,3,4, 5-tetrahydro-lH-l-benzazepine-2-one (3A) is conveniently prepared from 7-methoxy-l-tetralone (1A) , using known procedures described by Eaton, et al, J. Org. Chem. (1973) 38, 4071.
  • 7-Methoxy-l-tetralone which is commercially available, was transformed to 8-methoxy-2 , 3 , 4, 5- tetrahydro-lH-1-benzazepine-2-one (3A) via the corresponding oxime (2A) followed by the Beckmann rearrangement as illustrated in Scheme 1.
  • the Beckmann rearrangement can be achieved by a number of methods well known in the literature, including treatment of 7-methoxy-l-tetralone oxime (2A) with methanesulfonic acid and anhydrous phosphorous pentoxide at elevated temperatures .
  • Conversion of 8-methoxy-2 , 3 , 4 , 5-tetrahydro-lH-l- benzazepine-2-one (3A) to the 3-ethoxycarbonyl intermediate (4A) can be achieved by a number of methods familiar to those skilled in the art.
  • a suitable method involves use of LDA and diethyl carbonate or diethyl pyrocarbonate .
  • This catalyst system is effective in coupling reactions involving a variety of substrates, including electron poor anilines or electron-rich aryl bromides.
  • this cross coupling reaction tolerates a high degree of steric congestion at both aniline and aryl bromide.
  • this coupling strategy could be used to introduce a peptidomimetic side chain on 3-position of the l-l-benzazepine-2-one ring system including hydrophobic spacers, such as substituted 4-aminobenzoyl group.
  • 1 H and 13 C NMR spectra were recorded on Varian VXR 4000 in deuterochloroform(CDCl 3 ) with chloroform as an internal reference or in deuterated DMSO (DMSO-d 6 ) with DMSO as an internal reference unless noted otherwise.
  • 1 H and 13 C chemical shift assignments are based on detailed analysis of two dimensional or decoupled spectra when necessary. """H spectra were recorded at 400, usually 3.7 sec. acquisition time. 13 C spectra were recorded at 100MHz, 1.1 sec acquisition time. DEPT spectra were recorded at 400 MHz using 135 degree 1 H read pulse, usually 256 or 512 transients, 4 sec relaxation delay containing homospoil pulse.
  • Samples analyzed by GC-MS were acquired using Finnigan 4500 single quadrropole mass spectrometer utilizing electron impact (El) ionization; samples analyzed using direct probe El ionization or fast atom bombardment (FAB) ionization were acquired using a VG 70 SQ high resolution double-focusing magnetic sector instrument (EB geometry) ; and samples analyzed by electrospray ionization were acquired on a VG Trio 3 triple quadropole mass spectrometer.
  • El electron impact
  • FAB fast atom bombardment
  • TLC was performed on EM Reagents precoated Silica Gel 60 F-254 analytical plates (0.25 mm). Normal phase flash column chromatography was performed on ICN Silica, 6 ⁇ A (18-32 Mesh, 32-63 Mesh) . Normal phase gravity chromatography was performed on ICN Silica, 6 ⁇ A (63-200 Mesh). Purity and homogeneity of all materials were determined chromatographically, from MS, X H and 13 C NMR or combustion analysis. THF was distilled from sodium-benzophenone ketyl . Other reagents were obtained commercially and used as received unless otherwise specified. All reactions were performed under a static argon or nitrogen atmosphere in flame/oven dried glassware. Elemental analyses were performed by QTI Whitehouse, New Jersey.
  • the organic phase was treated with decolorizing carbon, stirred at room temperature for an hour and filtered through Celite. After drying over anhydrous magnesium sulfate the filtrate was evaporated to dryness.
  • the residual oil was purified by gravity column chromatography on silica gel using
  • reaction mixture was diluted with DCM (20 mL) , washed with water, dried over anhydrous Na 2 S0 4 , filtered and evaporated to dryness.
  • the crude product was purified by flash chromatography on silica column eluted with MeOH/DCM (1:19) .
  • reaction mixture After addition of Cs 2 C0 3 (0.342 g, 1.05 mmol) in one portion, the reaction mixture was purged with argon for 3 min, vigorously stirred and heated at 100°C for 22 hrs. The reaction mixture was diluted with DCM (20 mL) , percolated through a short column of Celite and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel column eluted with MeOH/DCM (1:9), provided the desired compound (40 mg, 7%) as a white crystalline product.
  • Table I contains additional embodiments of the invention according to formula I, wherein a and b are single bonds .
  • Table II contains additional preferred embodiments of this invention.
  • a and b are a single bond unless noted as a double (dbl) bond in the table below and:
  • the compounds of this invention can be administered as treatment for bacterial, viral or fungal infections by any means that produces contact of the active agent with the agent's site of action, the bacteria, virus or fungus in the body of an animal or plant or on the surface of nonliving objects. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents.
  • They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the compounds of the invention are useful for the treatment of infections in hosts, especially mammals, including humans, in particular in humans and domesticated animals (including but not limited to equines, cattle, swine, sheep, poultry, feline, canine and pets in general) and plants.
  • the compounds may be used, for example, for the treatment of infections of, inter alia, the respiratory tract, the urinary/reproductive tract, and soft tissues and blood, especially in humans.
  • the compounds may be used in combination with one or more therapeutic partners for the treatment of infections.
  • therapeutic partner or “therapeutic agent” as used herein and in the claims includes but is not limited to antibiotic (for example, tobramycin, cephalosporin) , steroids, vaccines, anti-oxidants, non-steroidal anti-inflammatories, antacids, antibodies, interferons, or cytokines .
  • therapeutic partners that may be co- administered with the compounds according to the invention include, but are not limited to imipenem, meropenem, biapenem, aztreonam, latamoxef (MOXALACTAMTM) , and other known beta- lactam antibiotics, benzylpenicillin, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin, ampicillin, amoxycillin, epicillin, ticarcillin, cyclacillin, pirbenicillin, azlocillin, mezlocillin, sulbenicillin, piperacillin, and other known penicillins.
  • imipenem imipenem
  • meropenem meropenem
  • biapenem biapenem
  • aztreonam latamoxef
  • latamoxef MOXALACTAMTM
  • beta- lactam antibiotics benzylpenicillin, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin
  • the penicillins may be used in the form of pro-drugs thereof, for example as in vivo hydrolysable esters, for example the acetoxymethyl, pivaloyloxymethyl, alpha-ethoxycarbonyloxyethy1 and phthalidyl esters of ampicillin, benzylpenicillin and amoxycillin; as aldehyde or ketone adducts of penicillins containing a 6- alpha-aminoacetamido side chain (for example hetacillin, metampicillin and analogous derivatives of amoxycillin) ; and as alpha-esters of carbenicillin and ticarcillin, for example the phenyl and indanyl alpha-esters.
  • pro-drugs thereof for example as in vivo hydrolysable esters, for example the acetoxymethyl, pivaloyloxymethyl, alpha-ethoxycarbonyloxyethy1 and phthalidyl esters of ampicillin,
  • Cephalosporins that may be therapeutic partners with the compounds according to the invention include, but are not limited to, cefatrizine, cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephapirin, cephamandole nafate, cephradine, 4- hydroxycephalexin, cephaloglycin, cefoperazone, cefsulodin, ceftazidime, cefuroxime, cefinetazole, cefotaxime, ceftriaxone, and other known cephalosporins. All of therapeutic partners may be used in the form of pro-drugs thereof.
  • the ratio of the amount of the compound according to the invention to the amount of the therapeutic partner may vary within a wide range.
  • the said ratio may, for example, be from 100:1 to 1:100; more particularly, it may, for example, be from 2:1 to 1:30.
  • the amount of the therapeutic will normally be approximately similar to the amount in which it is conventionally used per se, for example from about 50 mg, advantageously from about 62.5 mg, to about 3000 mg per unit dose, more usually about 125, 250, 500 or 1000 mg per unit dose .
  • the compound of the invention can be " administered separately or in the form of a single composition containing both active ingredients.
  • the compound of the invention and the therapeutic partner may be administered simultaneously or sequentially.
  • simultaneous administration include where two or more compounds, compositions, or vaccines which may be the same or different, are administered in the same or different formulation or are administered separately, e.g. in a different or the same formulation but within a short time (such as minutes or hours) of each other.
  • sequential administration include where two or more compounds, compositions or vaccines which may be the same or different are not administered together within a short time of each other, but may be administered separately at intervals of for example days, weeks, months or years .
  • Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety- nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
  • Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product .
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth) , powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • a compound of the present invention may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol mono
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose) , lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose) , surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical- formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be sterilized by, for example, filtration through a bacteria- retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient (s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils) , glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, bismuth, and tragacanth, and mixtures thereof .
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, bismuth, and tragacanth, and mixtures thereof .
  • Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate .
  • Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel .
  • Ophthalmic formulations are also contemplated as being within the scope of this invention.
  • the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
  • compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride
  • Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
  • the rate of drug release can be controlled.
  • biodegradable polymers include poly (orthoesters) and poly (anhydrides) .
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • intravenous and subcutaneous doses of the compounds of this invention for a patient when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg per kg per day, preferably from 5 to 500 mg.
  • Each unit dose may be, for example, 5, 10, 25, 50, 100, 125, 150, 200 or 250 mg of a compound according to the invention.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms
  • the compound or compositions of the invention is suspended in an agriculturally acceptable diluent, including but not limited to water or a fertilizer solution.
  • an agriculturally acceptable diluent including but not limited to water or a fertilizer solution.
  • glycerin can be added to the final diluted liquid formulation.
  • the compounds or compositions of the invention is mixed as a dry ingredient (s) with an inert agriculturally acceptable particulate dry carrier or diluent which provides a fine powdery formulation.
  • the agriculturally acceptable diluent is one that serves as a carrier for the low concentrations of compounds or compositions of the invention.
  • the dry diluent is one which readily suspends in suitable diluents for administration to plants, such as water.
  • the formulation is applied to the plant by any of a variety of art-recognized means.
  • the formulation can be applied to the plant surface by spraying.
  • the solution can be introduced injectably into a plant, for example, with a syringe, applied as a solid fertilized-like preparation for absorption by the roots at the base of a plant or a solution can be distributed at the base of a plant for root absorption.
  • the formulation can be applied as soon as symptoms appear or prophylactically before symptoms appear. Application can be repeated.
  • the present invention is the result of the unexpected discovery that substituted 1-benzazepines and analogs thereof defined by formulae I inhibit growth and/ or the life of bacteria.
  • pharmaceutical compositions containing the compounds of structural formula I inhibit bacteria and are useful as pharmaceutical agents for animals, especially mammals, including humans, for the treatment of bacterial diseases.
  • bacterial diseases those caused by, but are not limited to, Streptococcus spp. , Staphylococcus spp. , Clostridium spp. , Borrelia spp. , Haemophilus spp. , Pseudomonas spp. , Neisseria spp. , Coxiella spp. , Shigella spp.
  • Campylobacter spp. Enterococcae spp. , E. coli spp. , Helicobacter spp. , Klebsiella spp. , Moraxella spp. , Chlamydia spp . , Mycobacteria spp. , other nosocomial infections, respiratory infections and enteric infections.
  • MRSA methicillin resistant Staphylococcus aureus
  • Neisseria gonorrhoeae Mycobacteria tuberculosis
  • VRE vancomycin resistant Enterococcae
  • Helicobacter pylori Chlamydia pneumoniae, Chylamydia trachomatis and Camplylobacter jejuni .
  • the present invention is also useful in a method directed to treating infections in a host in need of such treatment, which method comprises administering a non-toxic (to the host) therapeutically effective amount of compounds represented by general Formula I.
  • the infected hosts are animals, preferably mammals, most preferably human, especially immunologically compromised individuals.
  • the infected host is a plant .
  • nonliving material such as but not limited to soil, surfaces, etc.
  • nonliving material such as but not limited to soil, surfaces, etc.
  • the present invention is also useful in a method of treating cancer, central nervous system, cardiovascular, inflammatory, or autoimmune disease in a host in need of such treatment, which method comprises administering a non-toxic (to the host) therapeutically effective amount of compounds represented by general Formula I.
  • the infected hosts are animals, preferably mammals, most preferably human.
  • the antibiotic preparation can also be used in a wide variety of agriculturally beneficial species such as tobacco, vegetables including cucumber, the Cruciferae, pea and corn, beans such as soy beans, grains including cotton, rice, alfalfa, oat and other cereals, fruits, including apple, pear, peach, plum, tomato, banana, prune and citrus fruits, tubers and bulbs including potatoes and onions, nuts including walnut, grasses including sugar cane and the like.
  • agriculturally beneficial species such as tobacco, vegetables including cucumber, the Cruciferae, pea and corn, beans such as soy beans, grains including cotton, rice, alfalfa, oat and other cereals, fruits, including apple, pear, peach, plum, tomato, banana, prune and citrus fruits, tubers and bulbs including potatoes and onions, nuts including walnut, grasses including sugar cane and the like.
  • the antibiotic preparation also is beneficial in the treatment of nursery plants and ornamental plants such as flowers, including chrysanthemum, begonia, gladiolus, geranium, carnations and gardenias.
  • the compositions of the instant invention also find use in the treatment of shade trees, forest trees, annual field crops and biannual field crops.
  • compositions of the invention can be used are Espinas, Cotoneaster, Phyrachanthas, Stranvaesis, Fraxinus, Pyrus, Malus, Capsicum, Cydonia, Crataegus and Soreus .
  • the compounds of the invention can also be used as animal growth promoters.
  • a compound of the invention is administered orally in a suitable feed.
  • the exact concentration employed is that which is required to provide for the active agent in a growth promotant effective amount when normal amounts of feed are consumed.
  • the addition of the active compound of the invention to animal feed is preferably accomplished by preparing an appropriate feed premix containing the active compound in an effective amount and incorporating the premix into the complete ration.
  • an intermediate concentrate or feed supplement containing the active ingredient can be blended into the feed.
  • the way in which such feed premixes and complete rations can be prepared and administered are described in reference books (such as such as "Applied Animal Nutrition", W.H. Freedman and CO., S. Francisco, USA, 1969 or “Livestock Feeds and Feeding" O and B books, Corvallis, Oreg. , USA, 1977) .
  • Antibacterial activity can be determined by several standard methods well known by those skilled in the art, including disc diffusions methods, broth dilution minimal inhibitory concentration (MIC) methods, etc., including the detailed method outlined below.
  • Anti-fungal activity can be determined by several standard methods well known by those skilled in the art (see for instance, U.S. 5,885,782), including disc diffusion methods, broth dilution minimal inhibitory concentration (MIC) methods and microplate growth assay.
  • MIC broth dilution minimal inhibitory concentration
  • Cultures of bacteria are initially brought up from the freezer stocks onto chocolate agar plates by streaking a loop- full, then incubated for 18 hours at 35-37°C in a 5% C02 incubator.
  • BHI Brain-Heart Infusion
  • nonliving material such as but not limited to soil, porous and non-porous surfaces, etc.
  • nonliving material such as but not limited to soil, porous and non-porous surfaces, etc.
  • the Helicobacter gastric colonization model is employed to evaluate the antibiotic activity against H. pylori or H. felis in vivo. For example, groups of female Balb/C mice ( ⁇ 6 weeks of age) are colonized, then treated with test compound (for example, one week later) . Following a period of time, half of the stomach from mice are scraped and plated onto bacterial culture medium, for instance BHI agar containing antibiotics and horse serum. The plates are incubated and colonies counted to determine whether any bacteria can be recovered in the gastrointestinal tract after treatment. Additionally, urease enzymatic assay, using methods generally known to those skilled in the art, is used to determine whether urease activity from Helicobacter is present. The absence of or reduction of bacteria on the culture plate or urease activity from treated mice, compared to that from non-treated mice, indicates the test substance is effective as an antibiotic against H. pylori or H. felis .
  • Example #178 Sepsis Model
  • the sepsis model is used to evaluate the prophylactic antibiotic efficacy of test compounds against a number of bacteria.
  • Basic methods include, for example, challenging mice intraperitoneally with a lethal amount of one or more bacteria, for example Staphylococcus aureus, and 7% mucin. Approximately 1 hr after challenge, the mice are treated by any route of administration, for example, subcutaneously, orally or intraperitoneally, with various concentrations of test compound. Vancomycin or another antibiotic is administered to a group of mice as the positive control and the placebo group of mice is administered the vehicle alone. Mortality is monitored for 96 hr. A reduction of the comparative mortalities or an increase in survival time in the various experimental groups provides evidence of efficacy of the test compound.
  • the wound healing model using methods generally known by those skilled in the art, is used to measure the efficacy of topically applied compounds against any bacteria, for example, Staphylococcus aureus .
  • Basic methods include, for example, inserting a suture impregnated with S. aureus subcutaneously on the shaved backs of mice. An incision is made along the cord. After 24 hrs, topical therapy with the test compound, placebo ointment or neomycin-polymyxin-B-bacitracin topical ointment (as control) (twice daily) is initiated. Ninety-six hours post-infection, the wound is sampled for microbial burden.
  • mice or rabbits are shaved. Gently scraping the skin, a superficial wound is created. About 10(6) cfu/20ul of any bacteria, for example, S aureus, is applied to the wound. The latter is occluded with a sterile plastic film and secured with an adhesive tape.
  • Topical therapy is employed using the above-mentioned treatment regimen.
  • the wound is swabbed to determine the microbial load.
  • a reduction is bacterial load in the wound is evidence that the compound is efficacious.
  • the Shigella sublethal wasting model is used to evaluate the antibiotic activity against Shigella flexneri or Shigella sonnei .
  • groups of mice are challenged intranasally with a sublethal wasting dose (-10 5 cfu) of either live Shigella flexneri or Shigella sonnei .
  • a sublethal wasting dose -10 5 cfu
  • mice are weighed and the mean group weight determined.
  • the mice are treated by any route of administration, for example, subcutaneously, orally or intravenously, with various concentrations of test compound.
  • a suitable antibiotic is administered to a group of mice as the positive control and the placebo group of mice is administered vehicle alone.
  • Antibiotic activity is measured by a reduction of weight loss.
  • the C. jejuni mortality model is used to evaluate the antibiotic activity against Campylobacter jejuni . For example, groups of mice are challenged with a single lethal
  • the C. jejuni fecal shedding model is used to evaluate the antibiotic activity against Campylobacter jejuni .
  • BALB/c mice are challenged nasally or orally with 10 ⁇ C. jejuni .
  • the mice are treated by any route of administration, for example, subcutaneously, orally or intraperitoneally, with various concentrations of test compound.
  • a suitable antibiotic is administered to a group of mice as the positive control and the placebo group of mice is administered vehicle alone.
  • the duration of fecal shedding is determined by monitoring over a 9 day period.
  • Antibiotic activity is measured by a reduction in numbers of bacteria shed.
  • Example # 183 Chlamydia pneumoniae lung model
  • the Chlamydia pneumoniae lung model is used to evaluate the antibiotic activity against Chlamydia pneumoniae .
  • BALB/c are inoculated intranasally with approximately 5 X 10 5 IFU of C. pneumoniae, strain AR39 in 100 ⁇ l of SPG buffer.
  • the mice are treated by any route of administration, for example, subcutaneously, orally or intravenously, with various concentrations of test compound.
  • a suitable antibiotic is administered to a group of mice as the positive control and the placebo group of mice is administered vehicle alone.
  • mice are taken from mice at days 5 and 9 post- challenge and immediately homogenized in SPG buffer (7.5% sucrose, 5mM glutamate, 12.5 mM phosphate pH 7.5) .
  • SPG buffer 7.5% sucrose, 5mM glutamate, 12.5 mM phosphate pH 7.5
  • the homogenate is stored frozen at -70°C until assay. Dilutions of the homogenate are assayed for the presence of infectious
  • the inoculum is centrifuged onto the
  • Example #184 Chlamydia trachomatis infertility model
  • the Chlamydia trachomatis infertility model is used to evaluate the antibiotic activi ty against Chlamydia trachomatis .
  • Female C3HeOuJ mice are administered a single intraperitoneal dose of progesterone (2.5 mg in pyrogen-free PBS, Depo-Provera, Upjohn) to stabilize the uterine epithelium.
  • progesterone 2.5 mg in pyrogen-free PBS, Depo-Provera, Upjohn
  • animals are infected by bilateral intraoviduct inoculation with approximately 5 X 10 5 inclusion forming units (IFU) of C. trachomatis (including but not limited to serovar F, strain Nil) in 100 ⁇ l of sucrose phosphate glutamate buffer (SPG) .
  • IFU inclusion forming units
  • mice are treated by any route of administration, for example, subcutaneously, orally or intravenously, with various concentrations of test compound.
  • a suitable antibiotic is administered to a group of mice as the positive control and the placebo group of mice is administered vehicle alone.
  • females from each group are caged with 8-10 week old male C3H mice for a 2 month breeding period to assess fertility (1 male for every 2 females per cage with weekly rotation of the males within each group, animals from different experimental groups were not mixed) . Palpation and periodic weighing are used to determine when animals in each pair become pregnant.
  • the parameters used to estimate group fertility are: F, the number of mice which littered at least once during the mating period divided by the total number of mice in that study group; M, the number of newborn mice (born dead or alive) divided by the number of litters produced in that group during the mating period; and N, the number of newborn mice (born dead or alive) divided by the total number of mice in that group.
  • Antibiotic activity is measured by an increase in fertility.
  • the N. gonorrhoeae mortality model is used to evaluate the antibiotic activity against Neisseria gonorrhoeae. For example, groups of mice are challenged with a single lethal dose of live N. gonorrhoeae ( ⁇ 10 8 cfu) and 7% mucin in endotoxin free PBS delivered intraperitoneally. Approximately
  • the animals are treated by any route of administration, for example, subcutaneously, orally or intraperitoneally, with various concentrations__of test, compound.
  • a suitable antibiotic is administered to a group of animals as the positive control and the placebo group of animals is administered vehicle alone.
  • Antibiotic activity is measured by a reduction in mortality.
  • the N. gonorrhoeae vaginal infection model is used to evaluate the antibiotic activity against Neisseria gonorrhoeae .
  • groups of mice are vaginally challenged with a dose of live N. gonorrhoeae in endotoxin free PBS.
  • the animals are treated by any route of administration, for example, subcutaneously, orally or intraperitoneally, with various concentrations of test compound.
  • a suitable antibiotic is administered to a group of animals as the positive control and the placebo group of animals is administered vehicle alone.
  • Vaginal clearance rates are determined for each group by daily sampling (swab) and cultivation of vaginal secretions.
  • Antibiotic activity is measured by a reduction in the number of N. gonorrhoeae. While the preferred embodiments of the invention have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne des 1-benzazépines substituées et leurs dérivés, utilisés en tant qu'agents antibactériens, des compositions, y compris des compositions pharmaceutiques, comprenant de tels composés, des procédés de production de ces composés, ainsi que des procédés d'utilisation de ces composés, permettant d'éliminer des bactéries ou d'inhiber la croissance bactérienne.
EP00977008A 1999-11-18 2000-11-07 1-benzazepines substituees et leurs derives Withdrawn EP1229913A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16616799P 1999-11-18 1999-11-18
US166167P 1999-11-18
PCT/US2000/030576 WO2001035964A1 (fr) 1999-11-18 2000-11-07 1-benzazepines substituees et leurs derives

Publications (2)

Publication Number Publication Date
EP1229913A1 true EP1229913A1 (fr) 2002-08-14
EP1229913A4 EP1229913A4 (fr) 2005-01-19

Family

ID=22602097

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00977008A Withdrawn EP1229913A4 (fr) 1999-11-18 2000-11-07 1-benzazepines substituees et leurs derives

Country Status (7)

Country Link
US (1) US6514965B1 (fr)
EP (1) EP1229913A4 (fr)
JP (1) JP2003514022A (fr)
AU (1) AU784646B2 (fr)
CA (1) CA2391498A1 (fr)
MX (1) MXPA02005070A (fr)
WO (1) WO2001035964A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392317A2 (fr) * 2001-05-16 2004-03-03 Antexpharma, Inc. 1-benzazepines substituees et leurs derives

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533824A1 (fr) * 2003-07-31 2005-02-10 Irm, Llc Composes bicycliques et compositions utilisees comme inhibiteurs pdf
US7323455B2 (en) * 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
WO2011038120A1 (fr) * 2009-09-25 2011-03-31 Pharmasol Corporation Revêtements de surface pour la peau
WO2011075375A1 (fr) * 2009-12-14 2011-06-23 Schering Corporation Composés tricycliques fusionnés pour le traitement de troubles inflammatoires
TWI638815B (zh) 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
JP2022055368A (ja) * 2019-02-19 2022-04-08 株式会社三和化学研究所 ベンゾアゼピン誘導体の製造方法及びその中間体

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3516987A (en) * 1966-04-25 1970-06-23 American Home Prod 1-methylsulfonyl-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine
EP0072352A1 (fr) * 1981-08-11 1983-02-16 Ciba-Geigy Ag Benzazepin-2-ones, procédé pour leur préparation, préparations pharmaceutiques contenant ces composés ainsi que ces composés pour utilisation thérapeutique
US4473575A (en) * 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
EP0504695A1 (fr) * 1991-03-21 1992-09-23 F. Hoffmann-La Roche Ag Nouveaux carboxyamides, leur préparation et compositions pharmaceutiques les contenant
US5310737A (en) * 1991-03-20 1994-05-10 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
WO1994019340A1 (fr) * 1993-02-18 1994-09-01 Ciba-Geigy Ag Derives de pyrimidine et leur utilisation comme pesticides
US5672596A (en) * 1992-08-28 1997-09-30 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509130A (en) * 1966-12-09 1970-04-28 Ciba Geigy Corp 2-amino-1-benzazepines
ZA825779B (en) * 1981-08-11 1984-04-25 Ciba Geigy Ag Benzazepins-2-ones
US5247080A (en) 1987-03-27 1993-09-21 Schering Corporation Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds
US5225436A (en) 1987-05-15 1993-07-06 Schering Corporation Aryl substituted naphthalene derivatives
US4885364A (en) 1988-11-23 1989-12-05 E. R. Squibb & Sons, Inc. Resolution process for benzazepine intermediates
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
GB9010404D0 (en) 1990-05-09 1990-06-27 Pfizer Ltd Therapeutic agents
WO1993000095A2 (fr) 1991-06-28 1993-01-07 Smithkline Beecham Corporation Antagonistes bicycliques de fibrinogene
NZ314922A (en) 1992-12-21 1998-11-25 Smithkline Beecham Corp Benzodiazepinones; nitrogen containing heterocyclic intermediates and pharmaceutical compositions
US5739128A (en) 1993-07-29 1998-04-14 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JPH09512806A (ja) 1994-05-07 1997-12-22 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物（ｉｉ）
JPH08277271A (ja) * 1995-04-06 1996-10-22 Eisai Co Ltd アミノベンズアゼピン−２−オン誘導体
ZA9610853B (en) 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6262068B1 (en) * 1997-02-21 2001-07-17 Bristol-Myers Squibb Company Lactam derivatives as antiarrhythmic agents
WO1998041510A1 (fr) * 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
AU5877500A (en) * 1999-06-15 2001-01-02 Neurogen Corporation Piperidinyl and piperazinyl substituted benzofused lactams

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3516987A (en) * 1966-04-25 1970-06-23 American Home Prod 1-methylsulfonyl-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine
EP0072352A1 (fr) * 1981-08-11 1983-02-16 Ciba-Geigy Ag Benzazepin-2-ones, procédé pour leur préparation, préparations pharmaceutiques contenant ces composés ainsi que ces composés pour utilisation thérapeutique
US4473575A (en) * 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
US5310737A (en) * 1991-03-20 1994-05-10 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
EP0504695A1 (fr) * 1991-03-21 1992-09-23 F. Hoffmann-La Roche Ag Nouveaux carboxyamides, leur préparation et compositions pharmaceutiques les contenant
US5672596A (en) * 1992-08-28 1997-09-30 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1994019340A1 (fr) * 1993-02-18 1994-09-01 Ciba-Geigy Ag Derives de pyrimidine et leur utilisation comme pesticides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199701 Derwent Publications Ltd., London, GB; Class B02, AN 1997-007474 XP002305565 & JP 08 277271 A (EISAI CO LTD) 22 October 1996 (1996-10-22) *
DATABASE WPI Section Ch, Week 199839 Derwent Publications Ltd., London, GB; Class B02, AN 1998-457046 XP002305567 & WO 98/35941 A1 (SHIONOGI & CO LTD) 20 August 1998 (1998-08-20) *
DATABASE WPI Section Ch, Week 199844 Derwent Publications Ltd., London, GB; Class B02, AN 1998-521150 XP002305566 & WO 98/41510 A1 (SHIONOGI & CO LTD) 24 September 1998 (1998-09-24) *
See also references of WO0135964A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392317A2 (fr) * 2001-05-16 2004-03-03 Antexpharma, Inc. 1-benzazepines substituees et leurs derives
EP1392317A4 (fr) * 2001-05-16 2005-10-19 Antexpharma Inc 1-benzazepines substituees et leurs derives

Also Published As

Publication number Publication date
AU784646B2 (en) 2006-05-18
US6514965B1 (en) 2003-02-04
EP1229913A4 (fr) 2005-01-19
JP2003514022A (ja) 2003-04-15
CA2391498A1 (fr) 2001-05-25
AU1470201A (en) 2001-05-30
WO2001035964A1 (fr) 2001-05-25
MXPA02005070A (es) 2003-09-25

Similar Documents

Publication Publication Date Title
JPH07509482A (ja) ベンゾジアセピン誘導体
JPH02289583A (ja) ５―アルキルキノロンカルボン酸類
JP2017502970A (ja) 窒素含有化合物及びその使用
JPH09512528A (ja) バソプレッシン拮抗物質としてのベンズアミド誘導体
AU2002327172B2 (en) Substituted 1-benzazepines and derivatives thereof
US6514965B1 (en) Substituted 1-benzazepines and derivatives thereof
AU2002327172A1 (en) Substituted 1-benzazepines and derivatives thereof
EP1358185A2 (fr) Antibact riens base de pyridoarylph nyle oxazolidinone, compositions et proc d s associ s
FI94640C (fi) Menetelmä farmaseuttisesti käyttökelpoisen (S)-7-(3-amino-1-pyrrolidinyyli)-1-syklopropyyli-6-fluori-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihapon valmistamiseksi
US7365071B2 (en) Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials
US20050245498A1 (en) Sterically-awkward beta-lactamase inhibitors
AU704115B2 (en) Zwitterionic forms of trovafloxacin
JPH0753376A (ja) 強迫疾患の治療用医薬を製造するためのｎ−（ピリジニル）−１ｈ−インドール−１−アミンの使用
CA2228528A1 (fr) Nouveaux sulfones de pename utilises en tant qu'inhibiteurs de la beta-lactamase
CN110392571B (zh) 取代的3-二烷基氨基甲基-哌啶-4-基-苯甲酰胺及其制备和使用方法
ES2203955T3 (es) 7-acilamino-3-(metilhidrazono)metil-cefalosporinas sustituidas antibacterianas y productos intermedios.
KR20050037583A (ko) 베타-락타마제 억제제 전구약물
KR20000010578A (ko) 사이클로알킬아미노메틸피롤리딘 유도체_
KR100274736B1 (ko) 6-엔-(엘-에이엘에이-엘-에이엘에이)-트로바플록사신 전구약물의 폴리모프
US11945830B2 (en) Antiviral heterocyclic compounds
IL39358A (en) 2-formyl-3-carbamoyl-quinoxaline-di-n-oxides,their production and pharmaceutical compositions containing them
KR102633087B1 (ko) 신규한 융합헤테로고리-카르보노하이드라조노일 디시아나이드 화합물 및 이의 용도
JPS59199693A (ja) インドリルグリシルセフアロスポリン誘導体
KR100756138B1 (ko) 글리신성 ｒ(+)-2-아미노-3-히드록시프로판산 유도체
US20100130509A1 (en) Novel antibiotics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020514;LT PAYMENT 20020514;LV PAYMENT 20020514;MK PAYMENT 20020514;RO PAYMENT 20020514;SI PAYMENT 20020514

A4 Supplementary search report drawn up and despatched

Effective date: 20041206

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 223/16 B

Ipc: 7A 61K 31/55 A

Ipc: 7A 61P 31/04 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080206